April 14, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Australian regenerative medicine company Mesoblast Limited 's $45 million deal with Celgene Corporation is a key step in recognizing emerging cell therapy and will help other Big Pharma firms find new strategies to expand their pipelines, Karine Kleinhaus , Pluristem Therapeutics 's divisional vice president for North-America, told BioSpace Tuesday. "The recognition of the value of the emerging cell therapy space that is communicated by this deal is very positive for all of us in the space," Kleinhaus told BioSpace .
http://ift.tt/1FF1gu2
http://ift.tt/1FF1gu2
No comments:
Post a Comment